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Abstract  
 
Background: Lupinus albus (LA) seed is a legume food used traditionally for the treatment of diabetes. The aim of this study was to investigate 
the effects of an aqueous extract of LA on lipid and glucose levels in normal and STZ induced Type 1 diabetic rats.  
Methods: Aqueous extract of LA was prepared and used for animal treatments. Diabetes was induced by a single intraperitoneal injection of 
streptozotocin (60mg/kg body weight). Effects of LA on oral glucose tolerance in normal and diabetic rats were investigated by giving a single 
dose of distilled water (controls), 200 or 400mg/kg LA extract, metformin 300mg/kg or glibenclamide 500µg/kg after 12 hours of fasting (time 0 
glucose). After 15 minutes, a glucose load (3g/kg) was given. Glucose levels were measured at 30, 60, and 120 minutes after glucose loading. To 
investigate long term effects, animals were given similar treatments daily for 4 weeks. At the end of the study, serum glucose, insulin, total 
cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL-C), very low density lipoprotein (VLDL-C) and high density lipoprotein 
(HDL-C) cholesterol levels were measured or calculated.  
Results: LA demonstrated significant (P<0.001) hypoglycaemic effects in normal rats but not in diabetic rats after acute and long term treatment. 
Normal LA treated rats showed higher (P<0.001) insulin levels compared to normal controls but insulin remained very low in diabetic rats. 
Diabetic rats showed diabetes associated weight loss in both treated and untreated rats. However, LA was effective in reducing atherogenic lipid 
levels (TC, TG, LDL-C VLDLC; P<0.001) with no change (P>0.05) in HDL-C.  
Conclusion: We conclude that the use of Lupinus albus among various communities may not be effective in treating hyperglycaemia in type 1 
diabetes but effective for treating diabetes induced dyslipidemia.  
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Introduction 
 
Plants have historically served as a source of food and drugs. The term “nutraceutical” was coined by Stephen De Feliceto blending the 
two plant functions (Scarafoni et al., 2007). Nutritionally, there is a worldwide shift towards using plant sources as protein in place of animal 
sources. This is deemed a healthier dietary choice towards the reduction of diet related diseases such as obesity, hypertension, cardiovascular 
disease and type II diabetes (Arnoldi and Greco, 2011).  As such, storage proteins from legumes have been the choice substitute for animal 
proteins. Soya bean is the most used legume that also possesses cholesterol reducing effects (Anderson et al., 1995; Sirtori et al., 1998; Sirtori et 
al., 2007).  
Lately, there has been a growing interest in other legumes as protein sources for human nutrition. One such legume is white lupin, 
Lupinus albus. This is an annual plant belonging to the class Leguminosae. It is grown in the Middle East and Africa as a food legume. In South 
Africa it is mostly grown in the Western Cape for animal feed (Brand and Brandt, 2000).  In addition to being consumed as food, L. albus seed is 
used medicinally. In traditional medicine the lupin seed is used as an anti-helminthic and anti-parasitic agent as well as an anti-diabetic agent 
(Eskander and Won Jun, 1995; Mansour et al., 2002). L. albus is rich in lupin proteins that belong to the vast families of 11S and 7S globulins of 
which conglutin-γ makes up 5% of the total globulins. Isolated lupin conglutin-γ has demonstrable hypoglycaemic effects in glucose loaded non 
diabetic experimental animals (Duranti et al., 1981; Magni et al., 2004; Bertoglio et al., 2011) and show insulin-mimetic effects in cultured cells 
(Komatsu and Hirano, 1991; Terruzzi et al., 2011). In addition, alkaloids from L. albus, is responsible for the bitter taste, also possess 
hypoglycaemic effects via increased insulin secretion in cultured pancreatic cells (Garzia Lopez et al., 2004; Oraby et al., 2008). Furthermore, 
crude aqueous extract of L. albus stimulates the release of insulin from cultured pancreatic islet cells (Pereira et al., 2001).  
Human trials using lupin conglutin-γ on healthy non-diabetic individuals confirmed its insulin releasing actions (Bertoglio et al., 2011). 
All these data were obtained in experimental conditions with intact pancreatic beta cells in vitro and in vivo. However, no work has been done to 
investigate the effects of L. albus in conditions of depleted pancreatic beta cells mirroring type 1 diabetes.  Type 1 diabetes is characterized by 
impaired insulin secretion leading to hyperglycaemia. Because insulin plays a major role in lipid metabolism, the absence of insulin is associated 
with dyslipidemia, a risk factor for cardiovascular disease and stroke (Pereira et al., 2001; Carmena, 2009).  As such, in current management of 
diabetes, statins are included to control the dyslipidemia. Indeed, hypolipidemic and anti-atherosclerotic effects of L. albus were demonstrated in 
high-fat diet fed animals (Fontanari et al., 2012; Marchesi et al., 2008).   
We therefore set out to investigate the effects of crude aqueous extract of L. albus in non diabetic and beta cell depleted streptozotocin 
(STZ)-induced type 1 diabetic rats. The rationale for using the aqueous extract is because alkaloids and peptides, components already 
demonstrated to have hypoglycaemic and hypolipidemic effects, are highly soluble in water.   
 
 
Materials and Methods 
Preparation of Crude Aqueous Extract of Lupinus albus (LA) 
 
250 grams of dried and crushed LA seeds were soaked in 1000ml of distilled water overnight with continuous agitation. The suspension 
was vacuum filtered through Whatman No 1 filter paper to remove the residue and the filtrate was freeze-dried (Modulyo Edwards) to give a solid 
yield of 28%. The powder was stored at -80°C until used for animal treatments.  
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Animals  
 
Adult male Wistar rats (250-300 grams weight) were purchased from a local supplier and housed in the Department of Physiology 
animal holding facility. They were maintained at a temperature averaging 25oC, 12:12 hour light: dark cycle, with water and pellet food (Epol-
SA) ad libitum. Institutional and national guide for the care and use of laboratory animals was followed at all times.  The study was approved by 
the institutional ethical committee, Walter Sisulu University.  
 
Induction of diabetes 
 
After two weeks of acclimatization in our facility, diabetes was induced in a group of normoglycemic rats as previously described by us 
(Duze et al., 2012). Briefly, animals were fasted overnight and diabetes was induced by a single intra-peritoneal injection of freshly prepared 
streptozotocin (STZ; Sigma) at a dose of 60mg/kg body weight in 0.1M citrate buffer (pH 4.5) to induce severe diabetes. Rats were given 5% 
glucose solution in place of water on the first night post STZ-treatment to counter STZ induced hypoglycaemia due to insulin leakage from 
damaged β cells (Szudelskit , 2001). After one week, fasting glucose levels were determined from the tail vein using a portable glucometer 
(Accucheck Active®) which is based on the glucose oxidase method. Severely diabetic animals with blood glucose >300mg/dL were used for this 
study.  
 
Oral Glucose Tolerance Test 
 
The oral glucose tolerance test (OGTT) was performed in both diabetic and non diabetic rats. The rats were randomly assigned into ten 
treatment groups of 6 animal groups. Distilled water was used as vehicle for all treatment solutions. Oral treatments were made using LA extract 
at 200 and 400 mg/kg body weight (b.w.); metformin 300 mg/kg b.w. and glibenclamide 500 µg/kg b.w. (Sigma Aldrich). LA doses chosen are 
equivalent to 50 (200mg/kg) and 100g (400mg/kg) dry weight of bean serving in a 70kg individual.  Treatment groups for the OGTT were as 
follows:  
1. Normal control 
2. Diabetic control 
3. LA (200mg/kg b.w) normal  
4. LA (400mg/kg b.w) normal  
5. LA (200mg/kg b.w) diabetic  
6. LA (400mg/kg b.w) diabetic  
7. Glibenclamide (500µg/kg b.w) normal  
8. Glibenclamide (500µg/kg b.w) diabetic  
9. Metformin (300mg/kg b.w) normal  
10. Metformin (300mg/kg b.w) diabetic  
 
Metformin (a biguanide) and glibenclamide (a sulphonylurea) are oral hypoglycaemic drugs prescribed for the treatment of diabetes. They were 
used as positive controls to establish whether LA acts to release insulin from beta cells (glibenclamide) or by increasing uptake by peripheral 
tissues (metformin). Glucose levels were measured after a 12 hour fast (time 0). Animals were then given the respective treatments (in 1ml 
volume) followed 15 minutes later by a glucose load (3 g/kg p.o. in 1ml volume). Control animals received 1ml distilled water p.o. Blood glucose 
levels were measured at 30, 60 and 120 minutes after glucose load using an Accucheck Active ® glucometer.  
 
Long term treatment protocol 
 
Eight animal groups from the OGTT study were continued on respective treatments for 28 days with weekly body weight and fasting 
blood glucose measurements.  However, glibenclamide and metformin were not used for normal rats to avoid drug-induced hypoglycaemia. On 
day 28, fasting glucose levels were recorded from the tail vein using an Accucheck Active ® glucometer.  Animals were euthanized by an 
overdose of phenobarbitone (65 mg/kg; Sigma). Blood was collected by cardiac puncture into plain dry tubes. After clotting, the blood was 
centrifuged at 10 000 rpm (Sigma) for 10 minutes and serum collected and stored at -70oC for insulin and lipid measurements. 
 
Assay for Insulin  
 
A high range rat insulin ELISA (Mercodia, AB, Uppsala, Sweden) was used for the analysis of insulin levels in serum samples as per 
manufacturer’s instructions. This was a colorimetric assay employing a double antibody method. Absorbance was read at 450nm and sample 
insulin concentrations were calculated from the standard curve and expressed as μU/mL. 
 
Lipid profiles 
 
Total cholesterol (TC), HDL-C and triglyceride (TG) concentrations were determined using an enzymatic direct colorimetric ELISA 
method as per manufacturer’s instructions (Labtest Diagnostics, Brazil). Values were reported in mg/dL. For the determination of very low 
density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C), Friedwald formulae were used as: VLDL-C=TG/5 
and LDL-C = TC – (VLDL-C+ HDL-C) (Friedewald et al., 1972). 
 
Acute toxicity studies 
 
Acute toxicity was determined in healthy adult Wistar rats of either sex as previously described (OECD, 2001; Asare et al., 2011).  Two 
groups of 5 rats/group received single oral dose of LA extract at 2500 and 5000 mg/kg body weight. The animals were observed continuously for 
1 hour, then hourly for the next 4 hours, intermittently over the next 48 hours and at least once a day for two weeks. Physical manifestations of 
toxicity such as writhing, gasping, salivation, hyperactivity, drowsiness and death were looked for during these animal observations. 
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Statistical analysis 
 
All data were presented as mean ± standard error of the mean (SEM). Statistical analysis between groups was performed using two-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. GraphPad Prism statistical package version 6.0 was used for 
statistical analyses. A difference in the means with P<0.05 was considered statistically significant. 
 
 
Results 
OGTT 
 
Initial mean fasting glucose levels were five-fold higher in diabetic compared to normal rats (Fig. 1A & B). As expected, there was 
increase in blood glucose levels after giving an oral glucose load for both normal and diabetic rats.  Blood glucose concentrations decreased to 
preloading or lower (metformin and glibenclamide) levels in normal rats but remained high in diabetic rats. The rise in glucose concentration after 
the glucose load in LA treated normal rats was significantly lower (P<0.001) compared to normal controls. This trend was similar to that obtained 
for reference drugs. In LA (200 and 400mg/kg) and reference hypoglycaemic drug (metformin and glibenclamide) treated rats AUCglucose was 
lower (P<0.001) compared to normal control rats (Fig. 1C). In contrast, LA extract showed no observable effect on glucose levels in STZ-induced 
diabetic rats showing a high AUCglucose. However, metformin showed hypoglycemic effects while glibenclamide, an insulin secretagogue did not 
(Fig. 1B & C). 
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Figure 1: Oral glucose tolerance in Lupinus albus treated rats for normal (A) and diabetic rats (B) calculated to show AUCglucose (C).  Data are 
presented as mean ±SEM. LA= Lupinus albus; Norm = normal; Dia = diabetic; Met = metformin; Glib = glibenclamide. For OGTT *P<0.05; 
**P<0.01 ***P<0.001 compared to controls; For AUCglucose ***P<0.001 (compared to normal control); 
###P<0.001 (compared to diabetic 
control). 
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Body weights 
 
Mean body weight gain of rats after 4 weeks of treatment are shown in Table 1. Body weights decreased (P<0.001) in STZ-induced 
diabetics; controls, LA and glibenclamide treated rats, compared to normal controls. However, metformin partially protected diabetic rats from 
diabetes associated weight loss (P<0.05 compared to normal controls). Body weights for normal LA treated rats were similar to normal controls 
(P>0.05; Table 1). 
 
Table 1: Body weights gained by rats at the end of the 28 day treatment period. Reference hypoglycaemic drugs were only used in treating 
diabetic rats.  
Treatment Normal 
Weight gain (g) 
Diabetic Rats 
Weight gain (g) 
Control 22.0 ± 1 -24.0 ± 2*** 
LA 200 mg/kg b.w. 21.0 ± 2 -18.0 ± 2*** 
LA 400 mg kg b.w. 22.0 ± 2 -18.0 ± 4*** 
Metformin  13.0 ± 1* 
Glibenclamide  -24.0 ± 2*** 
Data are presented as mean ±SEM (n=6/group). LA= Lupinus albus. *P<0.05; ***P<0.001 compared to normal control rats. 
 
Hypoglycaemic effects after long term treatment  
 
Results from daily administration of 200 and 400 mg/kg doses LA for 28 days showed significant (P>0.05, P<0.001) glucose lowering 
activity in normal rats showing  a  34% decrease in fasting blood glucose levels compared to untreated controls on day 28 (Fig. 2A). However, 
LA extract had no effect on blood glucose levels in STZ- induced diabetic rats at both doses, similar to the insulin secretagogue glibenclamide. 
However, metformin at 300mg/kg effectively reduced glucose levels (P>0.001) by 52% in STZ induced diabetic rats compared to the diabetic 
controls (Fig. 2B). 
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Figure 2: Blood glucose levels for normal (A) and STZ-induced diabetic rats (B) measured every seven days for 28 days. Data are presented as 
mean ±SEM. LA= Lupinus albus; Norm = normal; Dia = diabetic; Met = metformin; Glib = glibenclamide. ***P<0.001 compared to controls. 
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Insulin levels 
  Fasting insulin levels were significantly increased (P<0.001) in LA treated normal rats in a non-dose dependant manner. There was a 
60% increase in fasting insulin levels in LA treated normal rats compared to controls. Insulin remained low in all treatment groups of STZ-
induced diabetic rats (Table 2). 
 
Table 2: Comparison of the effects of LA on serum insulin concentrations in normal and STZ-induced diabetic rats. Reference hypoglycaemic 
drugs were only used in treating diabetic rats.  
Treatment Normal 
Insulin (µU/ml) 
Diabetic Rats 
Insulin (µU/ml) 
Control 11.25 ± 1.48 2.46 ± 0.07*** 
LA 200 mg/kg b.w. 17.52 ± 0.32*** 2.72 ± 0.05*** 
LA 400 mg kg b.w. 18.11 ± 0.51*** 2.83 ± 0.07*** 
Metformin  2.57 ± 0.05*** 
Glibenclamide  2.80 ± 0.04*** 
Blood samples were collected after 28 days of daily treatment. Data are presented as mean ±SEM (n=6/group). LA= Lupinus albus. ***P<0.001 
compared to normal control rats. Diabetic rat 
 
Lipid levels 
 
Despite the lack of hypoglycaemic effect in STZ-induced diabetic rats, LA exhibited significant hypolipidemic effects. LA treatment of 
STZ-induced diabetic rats at both 200 and 400 mg/kg b.w. resulted in a dose dependent decrease in TC (P<0.001; 18% and 27% respectively) and 
LDL-C (P<0.001; 26% and 37% respectively) compared to diabetic controls (Fig. 3A and C). LA treatment at both 200 and 400mg/kg b.w. 
resulted in a non-dose dependent decrease in TG (P<0.001; 21%) and VLDL-C (P<0.001; 24%; Figure 3 B and D). LA and glibenclamide 
treatment had no effect on HDL-C levels but metformin treatment increased HDL-C compared to diabetic controls (Fig 3E). In normal rats, LA 
treatment reduced TC and LDL-C (P<0.001) but not TG, VLDL-C and HDL-C concentration compared to normal controls (Fig. 3). Overall, 
diabetic rats demonstrated diabetes induced dyslipidemia.  
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Figure 3: Comparison of the effects of LA on serum lipids in normal and STZ-induced diabetic rats after 28 days of daily treatment. TC (A); TG 
(B); LDL-C (C); VLDL-C (D); HDLC (E). Reference hypoglycaemic drugs were only used in treating diabetic rats. Data are presented as mean 
±SEM. LA= Lupinus albus; Norm = normal; Dia = diabetic; Met = metformin; Glib = glibenclamide. ***P<0.001 compared to normal controls; 
###P<0.001 (compared to diabetic control). 
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Acute toxicity studies 
 
Toxicity studies carried out using oral doses of 2500 and 5000 mg/kg LA aqueous extract did not cause any obvious signs of toxicity as 
assessed by behavioral changes by the experimental rats.  Rats remained active and healthy after 2 weeks of observation. 
 
 
Discussion 
 
Diabetes mellitus is associated with dyslipidemia in both clinical and experimental diabetes (Rader et al., 2009; Istvan, 2002).  Many 
studies have demonstrated hypoglycaemic and hypolipidemic effects of medicinal plants in streptozotocin induced diabetic animal models (Kim 
et al., 2006; Aguilar-Santamaria et al., 2009; Gupta et al., 2009; Zhou et al., 2012; Patel et al., 2012). The STZ-induced diabetic rats in our study 
exhibited both hyperglycaemia and dyslipidemia. Destruction of pancreatic beta cells was confirmed by failure of STZ-induced diabetic rats to 
respond to the reference drug glibenclamide, an insulin secretagogue. In the present study, we sought to assess anti-hyperglycaemic and anti-
lipidemic effects of an aqueous extract of Lupinus albus seeds on beta cell depleted STZ-induced diabetic rats and in normal rats with intact 
pancreatic beta cells. Results showed that LA did not exhibit glucose-lowering effects in STZ induced diabetic rats after acute or chronic 
treatment. However, the extract acted to reduce fasting glucose levels in normal non-diabetic rats. Despite the absence of hypoglycaemic effects 
of LA in STZ induced diabetic rats, the extract was effective in lowering atherogenic cholesterol in both STZ-induced diabetic and non diabetic 
rats. 
We selected hypoglycaemic reference drugs based on their mechanism of action to assist in identifying possible mechanism of action of 
LA. Metformin exerts hypoglycaemic effects via increased peripheral glucose uptake while glibenclamide is an insulin secretagogue acting on 
pancreatic beta cells to release insulin. Our results imply that the mode of action of LA as a hypoglycaemic agent is insulin dependent thus 
ineffective in lowering glucose in type 1 diabetes, as mirrored by the STZ-induced diabetic rats used in this study. The absence of functional beta 
cells in our rat model was confirmed by the low insulin levels evident in the diabetic rats even after treatment with glibenclamide. LA was 
effective in lowering fasting glucose in normal rats with intact beta cells, in a similar manner to glibenclamide. 
Our most significant finding is the hypolipidemic effect of LA in STZ-induced diabetic rats. It is well established that elevated levels of 
TC, TG and LDL-C result in an increased risk of cardiovascular disease (Rader et al., 2009; Istvan, 2002). Insulin promotes lipid synthesis and 
suppresses lipid degradation by stimulation of transcription factors such as steroid regulatory element-binding protein (SREBP)-1c in the liver 
and in adipose tissue (Ferre, and Foufelle, 2007). The reduced insulin levels in STZ-induced diabetic rats in this study imply a non-insulin 
dependent mechanism in LA hypolipidemic effects. In a study in which rabbits were fed a high cholesterol diet, LA proteins were shown to be 
hypolipidemic and anti- atherosclerotic (Marchesi  et al., 2008). Additionally, in a study in which subjects with moderate hypercholesterolemia 
were given daily LA protein as a beverage, reduction in cholesterol levels and blood pressure were observed (Naruszewicz et al., 2006). In an in 
vitro study, treatment of liver hepatocellular (HepG2) cells with LA proteins resulted in increased activity of LDL receptors (Sirtori et al., 2004). 
Taken together these studies support the findings in our previous study and may point towards increased LDL receptor activity as the possible 
mechanism of action of LA in STZ-induced diabetic rats. Inhibition of HMG-CoA reductase (or 3-hydroxy-3-methyl-glutaryl-CoA reductase) the 
rate-controlling enzyme responsible for cholesterol synthesis via the mavelonate pathway is another potential target for LA action in lowering 
cholesterol levels. Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester from HDL to apolipoprotein B-containing lipoproteins and 
plays an important role in regulating the concentration and composition of HDL (Arai et al., 2011; Redondo et al., 2011). Thus, LA treatment may 
not affect CETP activity hence the unchanged HDL levels observed after 4 weeks of treatment in our study. 
Insulin is an anabolic hormone promoting protein synthesized in the tissues. In its absence there is muscle wasting and loss of tissue 
proteins resulting in weight loss (Marchesini et al., 1982; Basil and Gougeon, 2013). This was evident in the loss of weight observed in the present 
study. However LAwas not toxic at doses up to 5000 mg/kg. Thus, it has low toxicity. A previous study also reported a low toxicity with an LD50 
of >4000 mg/kg in mice (Stobiecki et al, 1993).  
This study demonstrates that L. albus has potential to treat the complications of Type 1 diabetes owing to its hypolipidemic effects. 
However, it may not possess hypoglycemic effects in Type 1 diabetic patients. Our findings imply that L. albus acts in a manner similar to 
glibenclamide, by increasing insulin secretion. The traditional use of L. albus in the treatment of diabetes among various communities may be 
associated with type 2 diabetes, the more common form of diabetes worldwide (Herman and Zimmet, 2012). Indeed this plant may be effective 
for type 2 diabetes in which pancreatic beta cells are still functional. Further studies to investigate effects of L. albus in a Type 2 diabetes model 
are essential.  
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